Table 1.
Background Characteristics of Patients Treated With Dual Antiplatelet Therapy 458 With Cilostazol and Aspirin or Clopidogrel and Those Treated With Single Antiplatelet Therapy With Aspirin or Clopidogrel Among Patients With Intracranial Arterial Stenosis After Ischemic Stroke
|
DAPT* (n=275) |
SAPT † (n=272) |
P value | |
|---|---|---|---|
| Sex, female | 101 (36.7%) | 79 (29.0%) | 0.056 |
| Age, y, median (IQR*, ‡ ) | 70 (65–76) | 70 (65–76) | 0.74 |
| Body mass index, median (IQR*, ‡ ) | 23.4 (21.6–25.9) | 23.4 (21.6–25.5) | 0.52 |
| Current cigarette smoking | 62 (22.5%) | 68 (25.0%) | 0.50 |
| Hypertension | 219 (79.6%) | 216 (79.4%) | 0.95 |
| Diabetes | 114 (41.5%) | 102 (37.5%) | 0.34 |
| Dyslipidemia | 171 (62.4%) | 162 (59.6%) | 0.49 |
| Chronic kidney disease | 28 (10.2%) | 9 (3.3%) | 0.0014 |
| Extracranial arterial stenosis | 53 (20.8%) | 49 (19.8%) | 0.77 |
| Coronary artery disease | 16 (5.8%) | 16 (5.9%) | 0.97 |
| Peripheral artery disease | 8 (2.9%) | 2 (0.7%) | 0.058 |
| History of ischemic stroke | 29 (10.5%) | 29 (10.7%) | 0.96 |
DAPT indicates dual antiplatelet therapy; IQR, interquartile range; and SAPT, single antiplatelet therapy.
*
Dual antiplatelet therapy with cilostazol and aspirin or clopidogrel.
†
Single antiplatelet therapy with clopidogrel or aspirin.
‡
Interquartile range.